CLOVES Syndrome Awareness and Support Overview

CLOVES Syndrome Awareness Day is held each year on 3 August to highlight a rare genetic disorder involving congenital tissue overgrowth and vascular anomalies. The syndrome is caused by mutations in the PIK3CA gene, which plays a role in biological processes such as angiogenesis.

This condition is part of a broader group known as PIK3CA-related overgrowth spectrum (PROS), which includes other syndromes with similar features. CLOVES was first described in the 19th century but only officially recognised in the early 21st century.

Awareness activities aim to provide information, support affected individuals and families, and encourage funding for research. In Australia, patients benefit from specialised diagnostic and treatment centres as well as national support programs for rare diseases.

Date and Purpose of the Commemoration Day

CLOVES Syndrome Awareness Day is observed annually on 3 August. This day was established to raise awareness about the rare overgrowth syndrome and to gather funds to support individuals living with CLOVES. On this day, people can show solidarity by wearing green clothing or attaching a green awareness ribbon, making donations to organisations that support CLOVES research and patients, and sharing information on social media using the hashtag #CLOVESAwarenessDay. The CLOVES Syndrome Community (CSC), founded in 2009 by a mother of a child diagnosed with CLOVES, actively promotes this awareness day. The primary goal of CSC is to provide support and resources to patients with CLOVES and their families.

Support and Treatment of CLOVES Syndrome in Australia

In Australia, CLOVES syndrome and other conditions within the PROS spectrum are classified as rare diseases. Patients and their families receive support through the national organisation Rare Voices Australia, which advocates for individuals affected by rare conditions. For those living with CLOVES syndrome who experience functional impairments, financial and social assistance is accessible via the National Disability Insurance Scheme (NDIS), providing essential resources to improve quality of life.

Clinical diagnosis of CLOVES syndrome in Australia often involves molecular genetic testing of the PIK3CA gene. This specialised testing is conducted in genetic laboratories affiliated with major university and children’s hospitals, ensuring accurate identification of the condition. Treatment of vascular malformations and related complications associated with CLOVES syndrome is typically managed within multidisciplinary vascular anomaly centres. Such centres are located in children’s hospitals across Sydney, Melbourne, and Brisbane, offering comprehensive care through coordinated specialist teams.

General Description of CLOVES Syndrome

CLOVES syndrome was first described by the German physician Hermann Friedberg in 1867, although it was only officially recognised in 2007. The acronym CLOVES stands for Congenital Lipomatous Overgrowth, Vascular malformations, Epidermal nevi, and Skeletal/spinal anomalies or Scoliosis. This syndrome is part of the PIK3CA-related overgrowth spectrum (PROS), which also includes MCAP syndrome and various localized forms of overgrowth. Overgrowth syndromes represent a group of rare genetic disorders characterised by an increase in tissue volume. CLOVES syndrome is caused by mutations in the PIK3CA gene, which encodes a protein involved in angiogenesis and other biological processes. It is related to other overgrowth syndromes such as hemihyperplasia, Klippel-Trenaunay syndrome, Proteus syndrome, and Sturge-Weber syndrome.

Clinical Manifestations of CLOVES Syndrome

Individuals diagnosed with CLOVES syndrome are born with the condition, with some symptoms present at birth or even detectable during prenatal development. A common clinical feature is the presence of a soft mass of fatty tissue, frequently observed on the abdomen, back, and legs. Additionally, certain body parts, typically the arms or legs, exhibit accelerated growth compared to other areas. Vascular malformations are another hallmark of CLOVES syndrome, involving abnormalities in blood or lymphatic vessels that can range in severity from mild to severe. Epidermal nevi, which are flat or slightly raised chronic skin lesions, are also characteristic of the syndrome. Skeletal and spinal anomalies are prevalent, including developmental defects in or around the spine, fixed core syndrome, and scoliosis. Beyond the symptoms encapsulated in the CLOVES acronym, affected individuals may experience other manifestations such as various skin abnormalities and the absence of a kidney.

Rarity, Challenges, and Research Support

CLOVES syndrome is an exceptionally rare condition, with only around 200 diagnosed cases worldwide. This rarity significantly impacts the availability of resources dedicated to understanding and managing the syndrome. Due to the limited number of patients, research into CLOVES syndrome faces challenges such as insufficient funding. Consequently, affected individuals often encounter restricted access to comprehensive informational resources, support networks, and effective treatment options. The scarcity of cases thus presents a considerable obstacle to advancing scientific knowledge and improving patient care for those living with CLOVES syndrome.